Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
| Revenue (TTM) | $207.65M |
| Gross Profit (TTM) | $113.69M |
| EBITDA | $-36.67M |
| Operating Margin | -15.80% |
| Return on Equity | -23.20% |
| Return on Assets | -5.92% |
| Revenue/Share (TTM) | $1.61 |
| Book Value | $2.46 |
| Price-to-Book | 2.19 |
| Price-to-Sales (TTM) | 3.67 |
| EV/Revenue | 2.275 |
| EV/EBITDA | 222.69 |
| Quarterly Earnings Growth (YoY) | 73.50% |
| Quarterly Revenue Growth (YoY) | 1.80% |
| Shares Outstanding | $130.78M |
| Float | $105.64M |
| % Insiders | 8.42% |
| % Institutions | 61.14% |
Volatility is currently expanding
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards.
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences:
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The company's management will also host a conference call to discuss its results, business developments and outlook beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FREMONT, Calif., and HAMBURG, Germany, Sept.
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CTKB and any ticker you trade — then tracks every position and per-strategy win rate.
